| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GALT | Common Stock | Award | $40 K | +23.3 K | +0.23% | $1.72 | 10.3 M | Jan 24, 2024 | Direct | F1 |
| holding | GALT | Common Stock | 27.7 K | Jan 24, 2024 | By Ed Uihlein Family Foundation | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GALT | Stock Option (right to buy) | Award | $0 | +50 K | $0.00 | 50 K | Jan 24, 2024 | Common Stock | 50 K | $1.72 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2024. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2024. |
| F2 | The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. |
| F3 | The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. |
| F4 | The options vest 100% on December 31, 2024. |